Atli Thorarensen

List of Publications by Year
in descending order

14	648	759233 12	1058476 14
papers	citations	h-index	g-index

14	14	14	1002
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chemical Biology, 2016, 11, 3442-3451.	3.4	127
2	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. Journal of Medicinal Chemistry, 2017, 60, 1971-1993.	6.4	111
3	PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. ACS Chemical Biology, 2019, 14, 1235-1242.	3.4	76
4	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 10665-10699.	6.4	55
5	ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. ACS Chemical Biology, 2014, 9, 1552-1558.	3.4	51
6	Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Freeâ€Energy Perturbation (FEP). ChemMedChem, 2016, 11, 217-233.	3.2	41
7	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. Scientific Reports, 2016, 6, 30859.	3.3	36
8	Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms. Drug Metabolism and Disposition, 2017, 45, 1-7.	3.3	30
9	The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization. Bioorganic and Medicinal Chemistry, 2021, 29, 115865.	3.0	29
10	Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6545-6553.	2.2	28
11	Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells. ACS Chemical Biology, 2017, 12, 2970-2974.	3.4	24
12	Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). ACS Medicinal Chemistry Letters, 2010, 1, 59-63.	2.8	22
13	Target the More Druggable Protein States in a Highly Dynamic Proteinâ€“Protein Interaction System. Journal of Chemical Information and Modeling, 2016, 56, 35-45.	5.4	11
14	New spleen tyrosine kinase inhibitors: patent applications published during 2011â€“2013. Pharmaceutical Patent Analyst, 2014, 3, 523-541.	1.1	7